Want to see HK:2633 full AI Analyst Report?
Top Page
Jacobson Pharma Corporation Limited
(2633)
Select Model
Select Model
Rating:70Outperform
Price Target:
HK$1.00
â–¼(-22.48% Downside)
Action:Upgraded
Date:07/20/26
The score is driven primarily by solid financial performance (strong margins, improving ROE, and manageable leverage), supported by attractive valuation (low P/E and high dividend yield). These positives are tempered by weaker technicals (price below major moving averages and negative MACD) and a notable recent decline in free cash flow.
Positive Factors
Strong margins
High gross (~43%) and net (~19%) margins indicate durable earnings power across the portfolio, supporting reinvestment and cash returns. Sustained margins suggest pricing power or efficient manufacturing, improving long-term cash generation and ability to fund R&D, marketing and dividends.
Negative Factors
Revenue volatility
Material top-line volatility, highlighted by a sharp 2024 decline and modest recent growth, undermines predictability of long-term revenue. Inconsistent sales trends complicate capacity planning, weaken scale economics for key products, and raise execution risk for new launches and sustained market-share gains.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong margins
High gross (~43%) and net (~19%) margins indicate durable earnings power across the portfolio, supporting reinvestment and cash returns. Sustained margins suggest pricing power or efficient manufacturing, improving long-term cash generation and ability to fund R&D, marketing and dividends.
Read all positive factors
Jacobson Pharma Corporation Limited (2633) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.00B
Dividend Yield8.57%
Average Volume (3M)206.45K
Price to Earnings (P/E)7.0
Beta (1Y)0.10
Revenue Growth-0.47%
EPS Growth-0.40%
CountryHK
Employees1,768
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.15
Shares Outstanding2,000,221,000
10 Day Avg. Volume257,000
30 Day Avg. Volume206,450
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.57
P/FCF Ratio12.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.16
Revenue Forecast (FY)HK$1.63B
Jacobson Pharma Corporation Limited Business Overview & Revenue Model
Company Description
Jacobson Pharma Corporation Limited, a subsidiary of Kingshill Development Limited, specializes in the production, promotion, and distribution of generic medications and branded healthcare products. Its market reach extends across Hong Kong, mainl...
How the Company Makes Money
Jacobson Pharma primarily makes money by selling pharmaceutical and healthcare products through a mix of distribution and self-developed/manufactured product sales. Key revenue streams typically include: (1) sales of proprietary or in-licensed pha...
Jacobson Pharma Corporation Limited Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
74
Positive
Cash Flow
58
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.57B | 1.58B | 1.47B | 1.79B | 1.60B |
| Gross Profit | 677.90M | 692.94M | 620.48M | 747.17M | 620.52M |
| EBITDA | 506.97M | 558.87M | 475.11M | 462.04M | 415.49M |
| Net Income | 301.62M | 300.83M | 266.97M | 251.04M | 177.67M |
Balance Sheet | |||||
| Total Assets | 3.56B | 3.65B | 3.49B | 5.38B | 4.76B |
| Cash, Cash Equivalents and Short-Term Investments | 369.86M | 509.05M | 411.94M | 1.04B | 478.65M |
| Total Debt | 910.90M | 773.21M | 749.38M | 1.60B | 1.41B |
| Total Liabilities | 1.22B | 1.17B | 1.09B | 2.12B | 1.80B |
| Stockholders Equity | 2.32B | 2.45B | 2.37B | 2.74B | 2.49B |
Cash Flow | |||||
| Free Cash Flow | 200.52M | 278.39M | 354.85M | 585.23M | 345.89M |
| Operating Cash Flow | 336.70M | 526.78M | 484.36M | 648.24M | 409.76M |
| Investing Cash Flow | -232.70M | -297.76M | 43.34M | -44.09M | -52.75M |
| Financing Cash Flow | -242.18M | -131.30M | -1.05B | -45.64M | -357.89M |
Jacobson Pharma Corporation Limited Technical Analysis
Positive
1.29
Price Trends
1.01
Negative
1.05
Negative
1.13
Negative
Market Momentum
>-0.01
Negative
49.55
Neutral
-73.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2633, the sentiment is Positive. The current price of 1.29 is above the 20-day moving average (MA) of 0.99, above the 50-day MA of 1.01, and above the 200-day MA of 1.13, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.55 is Neutral, neither overbought nor oversold. The STOCH value of -73.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2633.
Jacobson Pharma Corporation Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$779.10M | 7.81 | 13.59% | 7.40% | 10.63% | 39.44% | |
75 Outperform | HK$1.48B | 5.52 | 6.78% | 6.40% | 6.55% | 36.62% | |
70 Outperform | HK$2.00B | 6.95 | 13.26% | 8.91% | -0.47% | -0.40% | |
53 Neutral | HK$6.77B | -5.57 | -4.98% | 0.26% | -15.80% | -298.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$339.89M | 84.72 | 0.34% | 84.69% | -8.30% | -44.44% | |
43 Neutral | HK$144.43M | -4.75 | -21.66% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:2633
Jacobson Pharma Corporation Limited
1.05
-0.35
-25.00%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.34
-0.84
-38.48%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.04
-12.86%
HK:1498
PuraPharm Corp. Ltd.
0.26
-0.18
-40.91%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.00
-0.17
-14.60%
HK:0239
Pak Fah Yeow International Limited
2.50
0.19
8.13%
Jacobson Pharma Corporation Limited Corporate Events
Jacobson Pharma Sets Virtual AGM, Proposes Dividend and Share Mandates
Jul 16, 2026
Jacobson Pharma Corporation Limited has called a virtual annual general meeting on 11 August 2026 to present its audited financial statements for the year ended 31 March 2026 and seek shareholder approval on a range of governance matters. The boar...
Jacobson and JBM in HK$74.7 Million Connected Deal for Li Chung Shing Tong Stake
Jun 29, 2026
Jacobson Pharma’s subsidiary Europharm has agreed to sell 124,500 shares in Li Chung Shing Tong (Holdings) Limited to JBM’s subsidiary Po Chai Herbal for HK$74.7 million, valuing each share at HK$600. The consideration will be funded b...
Jacobson Pharma Holds Profit Steady Amid Slight Revenue Dip and Cuts Dividend Payout
Jun 23, 2026
Jacobson Pharma reported revenue of HK$1,569.5 million for the year ended 31 March 2026, a slight 0.5% decline from the prior year, while profit attributable to shareholders inched up 0.3% to HK$301.6 million. The modest profit growth, delivered d...
Jacobson Pharma Declares Final Cash Dividend for FY2026
Jun 23, 2026
Jacobson Pharma Corporation Limited has declared a final ordinary cash dividend of HKD 0.0475 per share for the financial year ended 31 March 2026, subject to shareholder approval on 11 August 2026. The ex-dividend date is set for 7 September 2026...
Jacobson Pharma to See Retirement of Independent Non-Executive Director in 2026
Jun 23, 2026
Jacobson Pharma Corporation Limited announced that independent non-executive director Kenneth Young Chun Man will retire from the board at the conclusion of the company’s annual general meeting on 11 August 2026, as he will not stand for re-...
Jacobson Pharma Sets June Board Meeting to Approve Annual Results
Jun 4, 2026
Jacobson Pharma Corporation Limited has scheduled a board meeting for 23 June 2026 to review and approve the audited annual results for the year ended 31 March 2026 and to consider a potential final dividend. The meeting will also address other co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.